Search Articles
SAN DIEGO – Directors of Orexigen Therapeutics awarded themselves more than the 1.5 million annual stock options allowed by shareholders, according to a federal derivative complaint.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.